



**Chinese Medical Doctor Association
Pharmacoeconomics Chapter Annual Report 2013**

TO:

Board of Directors

International Society for Pharmacoeconomics and Outcomes Research

3100 Princeton Pike, Suite 3E

Lawrenceville, NJ 08648 USA

PREPARED BY:

Dr. Wei Zhang, Vice Director

Chinese Medical Doctor Association Pharmacoeconomics Professional Committee
(ISPOR Chinese MDA-PE Chapter)

Chinese Medical Doctor Association

Room 519, No.3 Building

No.11 Dongzhimen Wai Xinzhong Road, Dongcheng District, Beijing, P.R. China

Email: pe@cnda.org.cn; wzhang@ceibs.edu

Background:

Chinese Medical Doctor Association Pharmacoeconomics Committee was approved by ISPOR in January 2006.

The Chapter now has 341 members and the committee consists of well-known professionals on Pharmacoeconomics, Clinical Medicine as well as Pharmacy. Current President is Dr. Wei Zhang, MD, PhD, Associate Professor, Guanghua School of Management, Peking University, Beijing, P. R. China.

The Chapter has always been devoted to disseminating the knowledge and skills of Pharmacoeconomics and Outcomes Research. Much progress has been made in promoting Pharmacoeconomics application in health system reform through embranchments of CDMA.

For more information, please visit http://www.ispor.org/regional_chapters/Chinese_MDA-PE/index.asp.

Enclosure: Chinese MDA-PE Chapter Annual Report 2013

Chinese MDA-PE Chapter Annual Report 2013

(Chinese Medical Doctor Association Pharmacoeconomics Committee)

Accomplishments Made in 2013

Accomplishments	Major Aspects
Mission	Promote the development and application of Pharmacoeconomics in China, and provide evidence and suggestion to pharmaceutical business and health department by applying Pharmacoeconomics and Clinical Practice Economic Evaluation methodology to appraise the innovation of technology, organization and policy in health sector.
Membership development	Members of Chinese MDA-PE Chapter include professionals and young researchers from universities and research institutes, clinicians in general hospitals, community service centers, and hospitals in rural areas, as well as those working in pharmaceutical business.
Studies & Projects	<p>We devoted major efforts to develop and implement drug formularies and standard treatment guidelines in rural area in China. The formularies and guidelines have been compiled and first put into use in Anhui province.</p> <p>1) We initialed several studies of Pharmacoeconomic Evaluation, including <i>Pharmacoeconomic Evaluation of Different Therapeutic Schemes of Chronic Hepatitis B</i>.</p> <p>2) We also have been advancing the project of <i>Innovation of Disease Management System in Rural China</i> which was initialed by the Ministry of Health and the World Bank since 2011. Besides, we have completed the research project of <i>Applicatin of Clinical Practice Economic Evaluation in Health Insurance Management</i>.</p>
Education & Training	The chapter also made some significant steps forward in education and training in 2013. We held 5 useful courses in Beijing, Anhui, Shaanxi, etc., such as the training course of <i>Drug Formularies and Standard Treatment Guidelines for Rural Area, Application of Economic</i>

Evaluation in Essential Drug System and Health Insurance System to provide opportunities for them to get continuing education credits that accredited on a national scale and help capacity building. Those courses also can train doctors and other relevant personnel in different clinical disciplines to disseminate the knowledge and skills of Pharmacoeconomics and Outcomes Research. About 200 people attended courses mainly including clinicians ,pharmaceutical business workers and relative administrators.

**Contribution to
health reform in
China**

The chapter has always been working hard to provide evidence and suggestion in essential drug policy , the third party payment model of health insurance , in order to help forward the establishment of national essential drug system, by conducting pharmaceutical evaluation research.

We have been contributing our great efforts in the project of *Innovation of Disease Management System in Rural China* which is an important part of the *Health XI Project* since 2011. The disease management innovative solutions in rural China we proposed would contribute to the establishment of health insurance system for rural residents, improvement of health service system, and exploration of health system reform in rural areas of different development levels.

We devoted major efforts to develop and implement drug formularies and standard treatment guidelines in rural area in China this year. This project would play a significant role in helping health sectors in rural area improve health service quality, provide critical public health service, control health expenditure.

**Domestic
&
International
Collaboration**

We have established good cooperative relationship with the government, several organizations and companies in health sector. We have furthered our collaboration relationship with them by advancing the important part of the *Health XI Project* directed by MOH, continuing projects with China Europe International Business School, doing

Pharmacoeconomics evaluation with Analysis Group in USA ,China Pharmaceutical University, and Peking University Health Science Center as well.

The Plan of 2014

Further development of membership

We expect to make significant development in membership recruitment in 2014, mainly planning to recruit clinicians, by holding training courses providing opportunities for them to get continuing education credits and conferences where they could share their experience with other professionals. Training courses and conferences will be held at Beijing, Shanghai and Guangzhou, especially for senior leaders and community clinicians.

Developing international exchange program

We plan to continue international exchange programs to widen the view of Pharmacoeconomics research and learn advanced application of Pharmacoeconomics from developed countries by inviting some foreign professionals to join in our research and give lectures about their achievements in Pharmacoeconomics.

Research prospect

We will follow our routing research plan of researching on drug utilization and pharmacoeconomics evaluation and accomplish the projects which is still in progress. Meanwhile, we will go on exploring an optimal integration research pattern in Pharmacoeconomics and clinical protocols. Moreover, providing evidence and suggestion in essential drug policy and health insurance by conducting pharmaceutical evaluation research will still be our task in 2014.
